Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743204 | 0.93 | MAOB (0.39) | HIF1APLA2G1BATG4BKMT2A | |
| SCHEMBL7743200 | 0.93 | MAOB (0.39) | HIF1APLA2G1BATG4BKMT2A | |
| SCHEMBL6841787 | 0.93 | PTGS2 (0.38) | PTGS2HIF1ASMN1; SMN2NPC1 | |
| SCHEMBL8711326 | 0.93 | PTGS2 (0.38) | PTGS2HIF1ASMN1; SMN2NPC1 | |
| SCHEMBL17949973 | 0.89 | HIF1A (0.42) | HIF1ARAB9AGAASMN1; SMN2CYP1A2 | |
| SCHEMBL8725188 | 0.83 | HIF1A (0.40) | PTGS2HIF1A | |
| SCHEMBL8725191 | 0.83 | HIF1A (0.40) | PTGS2HIF1A | |
| SCHEMBL7863544 | 0.83 | HIF1A (0.40) | PTGS2HIF1A | |
| SCHEMBL7736847 | 0.83 | MAOB (0.45) | HIF1A | |
| SCHEMBL6841529 | 0.83 | MAOB (0.45) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039220-A1 | Process for the preparation of pesticides | FAROOQ SALEEM (CH) | 2004-02-26 | — | — | US | disclosed |
| EP-0876333-B1 | PROCESS FOR THE PREPARATION OF PESTICIDES | BAYER AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6156923-A | Process for the preparation of pesticides | NOVARTIS CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039220-A1 | Process for the preparation of pesticides | CHRM1, CHRM2, F7 | PTGS2 604/4885HIF1A 3590/4885RAB9A 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.